FPI-2265

DRUG3 trials

Sponsors

Fusion Pharmaceuticals Inc.

Conditions

Metastatic Castration Resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer

Phase 2

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Active, not recruitingNCT05219500

Fusion Pharmaceuticals Inc.Metastatic Castration Resistant Prostate Cancer

Start: 2021-12-16End: 2026-07-31Target: 115Updated: 2026-04-03

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, not recruitingNCT06402331

Fusion Pharmaceuticals Inc.Metastatic Castration-resistant Prostate Cancer

Start: 2024-03-05End: 2031-01-23Updated: 2026-04-08

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, not recruitingNCT06909825

Fusion Pharmaceuticals Inc.Metastatic Castration-resistant Prostate Cancer

Start: 2025-02-26End: 2027-05-01Target: 85Updated: 2026-09-03

Related Papers

Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Cancer Research2024-04-056 citations

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations